The Therapeutic Goods Administration (TGA) has cleared DigniCap Delta for use by health care providers in Australia.

The new device is the fourth generation of The DigniCap Scalp Cooling System and is indicated to prevent chemotherapy-induced hair loss in patients with solid tumors.

“DigniCap Delta changes everything about the way scalp cooling is done today,” said William Cronin, CEO of Dignitana. “The Delta system improves the clinical process, reduces nursing intervention and optimizes patient outcomes. This new device, developed along with our partner sites, allows them to accomplish all three of these objectives. We are thrilled to offer patients and clinicians this state-of-the-art advancement in cancer care. Australia is a very important market for us and, as scalp cooling has become a standard of care for patients here, the Delta device will enable our partner sites to offer this valuable therapy option to more patients and much more efficiently.”

DigniCap Delta is now available to hospitals in Australia through Dignitana’s longtime distribution partner, Aurora BioScience, with first deliveries expected in October.